Latest Drugs, Latest Approval in Peripheral opioid receptor antagonists

What are Peripheral opioid receptor antagonists?

Peripheral opioid receptor antagonists bind to the peripheral opioid receptors, such as those in the gastrointestinal tract and block unwanted effects caused by opioids.

They are not able to penetrate the blood brain barrier so do not antagonize central nervous system opioid receptors, therefore the analgesic effects of opioids is not affected.

Peripheral opioid receptor antagonists are given with opioids to prevent opioid-induced constipation.

Name Updated
Methylnaltrexone (oral/injection) (Methylnaltrexone (oral/injection) [ meth-il-nal-trex-own ]) 17-Aug-2023
Alvimopan (Alvimopan [ al-vi-moe-pan ]) 16-Aug-2023
Naloxegol (Naloxegol [ nal-ox-ee-gol ]) 14-Aug-2023
Naldemedine (Naldemedine [ nal-dem-e-deen ]) 14-Aug-2023
Symproic (Naldemedine [ nal-dem-e-deen ]) 14-Jul-2023
Relistor (Methylnaltrexone (oral/injection) [ meth-il-nal-trex-own ]) 14-Jul-2023
Movantik (Naloxegol [ nal-ox-ee-gol ]) 13-Jul-2023
Entereg (Alvimopan [ al-vi-moe-pan ]) 13-Jul-2023